Subscribe To
Attention reit shoppers: a blue light special in the cell tower sector
Crown Castle and American Tower, two cell tower REITs, are undervalued and offer attractive yields. Crown Castle is trading at its cheapest level in a...
October 23, 2023, 7:00 am
The death of renewables? - september dividend income report
In September 2017, I received slightly over $100K from my former employer, representing the commuted value of my pension plan. NextEra Partners announ...
October 21, 2023, 3:19 am
Csi compressco lp announces quarterly distribution and schedule for third quarter 2023 earnings release conference call and webcast
THE WOODLANDS, Texas , Oct. 19, 2023 /PRNewswire/ -- CSI Compressco LP ("CSI Compressco") (NASDAQ: CCLP) announced today that the board of directors o...
October 19, 2023, 8:00 pm
Hexagon: update after 2 months of mostly negative ror, i still say 'buy'
Hexagon's share price has become attractive, allowing for a 16.5% annualized rate of return through a c...
October 18, 2023, 9:23 pm
Hdv: solid dividend etf but lacking upside potential
HDV has a higher starting yield of 4% as well as an annualized dividend growth rate of 5% over the last...
October 18, 2023, 6:02 pm
Mesabi trust looks attractive with estimated forward yield of 8.2% to 11.4%
Mesabi Trust distributions were scrapped because Cleveland-Cliffs temporarily idled its mine. Iron ore demand could benefit from China's construction ...
October 18, 2023, 2:08 pm
These 3 buy-rated stocks are long-term outperformers
When it comes to outperformance, all three of these stocks fit the criteria, delivering at least a 20% annuali...
October 17, 2023, 4:32 pm
I was wrong, tesla is a buy at 29% undervaluation despite the ev price war
Tesla Inc. boasts industry-leading profitability margins, which are set to expand as the adoption of electric vehicles advances and market leaders eme...
October 17, 2023, 3:10 pm
Fca restricts modulr's customer onboarding amid regulatory changes
The UK's Financial Conduct Authority (FCA) has imposed customer onboarding restrictions on Payments-as-a-Service provider Modulr until it aligns with ...
October 17, 2023, 12:43 pm
Kold: a speculative short term tool
The ProShares UltraShort Bloomberg Natural Gas ETF aims to provide investors with -2x daily performance of the Bloomberg Natural Gas Subindex. The fun...
October 16, 2023, 10:10 pm
Cousins properties: a 6.8% yield from class a sun belt offices
Cousins Properties offers a stable quarterly cash dividend with a 6.8% annualized forward dividend yiel...
October 16, 2023, 1:39 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm